CN107837311B - Application of Honglong analgesic tablet in preparation of nerve cell protective preparation - Google Patents
Application of Honglong analgesic tablet in preparation of nerve cell protective preparation Download PDFInfo
- Publication number
- CN107837311B CN107837311B CN201610834515.0A CN201610834515A CN107837311B CN 107837311 B CN107837311 B CN 107837311B CN 201610834515 A CN201610834515 A CN 201610834515A CN 107837311 B CN107837311 B CN 107837311B
- Authority
- CN
- China
- Prior art keywords
- honglong
- extract
- analgesic
- preparation
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 79
- 210000002569 neuron Anatomy 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 230000001681 protective effect Effects 0.000 title claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 53
- 230000007246 mechanism Effects 0.000 claims abstract description 12
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 10
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 10
- 206010061218 Inflammation Diseases 0.000 claims abstract description 9
- 230000004054 inflammatory process Effects 0.000 claims abstract description 9
- 230000009471 action Effects 0.000 claims abstract description 5
- 238000007796 conventional method Methods 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 23
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000002024 ethyl acetate extract Substances 0.000 claims description 20
- 239000000469 ethanolic extract Substances 0.000 claims description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 12
- 244000028419 Styrax benzoin Species 0.000 claims description 11
- 235000000126 Styrax benzoin Nutrition 0.000 claims description 11
- 235000008411 Sumatra benzointree Nutrition 0.000 claims description 11
- 229960002130 benzoin Drugs 0.000 claims description 11
- 235000019382 gum benzoic Nutrition 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 239000006286 aqueous extract Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 241000501953 Aconitum pendulum Species 0.000 claims description 2
- 241001586435 Aconitum tanguticum Species 0.000 claims description 2
- 244000020518 Carthamus tinctorius Species 0.000 claims description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 2
- 241000530047 Herpetospermum pedunculosum Species 0.000 claims description 2
- 241000382298 Lagotis Species 0.000 claims description 2
- 241001071917 Lithospermum Species 0.000 claims description 2
- 241001530209 Swertia Species 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 241001092413 Chrysosplenium Species 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000002011 neurocytoprotective effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 14
- 208000028867 ischemia Diseases 0.000 abstract description 13
- 230000006378 damage Effects 0.000 abstract description 10
- 210000005036 nerve Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 36
- 239000003814 drug Substances 0.000 description 29
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 26
- 229940079593 drug Drugs 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 238000000605 extraction Methods 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 10
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 description 9
- 108010012715 Superoxide dismutase Proteins 0.000 description 9
- 238000003809 water extraction Methods 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 229960002989 glutamic acid Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 230000005779 cell damage Effects 0.000 description 5
- 208000037887 cell injury Diseases 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 208000018380 Chemical injury Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 208000036815 beta tubulin Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000015489 Emblica officinalis Nutrition 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000277583 Terminalia catappa Species 0.000 description 2
- 235000011517 Terminalia chebula Nutrition 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000093 cytochemical effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 244000132619 red sage Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000243695 Brachyporus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000123346 Chrysosporium Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000729176 Fagopyrum dibotrys Species 0.000 description 1
- 241000208812 Flaveria bidentis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000071493 Iris tectorum Species 0.000 description 1
- 241000855811 Marinula Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000000037 effect on migraine Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- YNCMLFHHXWETLD-UHFFFAOYSA-N pyocyanin Chemical compound CN1C2=CC=CC=C2N=C2C1=CC=CC2=O YNCMLFHHXWETLD-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/09—Lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an application of Honglong analgesic tablets in preparing a nerve cell protective preparation, which comprises an extract prepared by a conventional method according to the formula of the Honglong analgesic tablets, and the extract has the action mechanism of removing free radicals and reducing NO or NF-kB inflammation. The invention overcomes the technical prejudice, firstly provides the Honglong analgesic tablet and the extractive thereof with the nerve protection function, improves the survival rate of nerve cells by removing free radicals, reducing the damage of the nerve cells caused by a large amount of NO and the like, and can obviously inhibit the expression of NF-kB in the nerve cells damaged by ischemia-reperfusion so as to inhibit the damage of inflammatory reaction on the nerve cells.
Description
Technical Field
The invention relates to an application of Honglong analgesic tablets in preparing a nerve cell protective preparation, belonging to the technical field of medicines.
Background
The Honglong analgesic tablet is a Tibetan ancient empirical prescription and is loaded in the standard issued by the Tibetan medicine ministry, and the standard number is as follows: WS-10659(ZD-0659) -2002-2011Z, which consists of 112.0g of fossil fragments, 67.0g of India swertia herb, 67.0g of safflower, 14.0g of Chrysosporium japonicum, 67.0g of Sichuan flaveria bidentis, 14.0g of aconitum pendulum, 67.0g of aconitum tanguticum, 6.6g of bear gall powder, 13.5g of Quanhua, 13.5g of herpetospermum pedunculosum seeds, 13.5g of Marinula vesiculosa, 13.5g of lithospermum, 67.0g of Lagotis brachyporus breviflorus, 13.0g of benzoin and 35.0g of mother-of-pearl, has the effects of restoring consciousness, inducing resuscitation, dredging collaterals and relieving pain, and is used for treating migraine and angioneurotic headache caused by stasis and obstruction of brain collaterals.
The Honglong analgesic tablet has better effect on migraine and angioneurotic headache caused by stasis blocking brain collaterals in clinic, no specific pharmacological mechanism research exists in the existing literature, and the main pharmacological mechanism of the analgesic effect is presumed to be the functions of improving blood supply and resisting inflammation and relieving pain by analyzing the formula. The existing literature does not find the research of the protective effect of the Honglong analgesic tablet on nerve cells.
Disclosure of Invention
The invention aims to provide application of Honglong analgesic tablets in preparation of a nerve cell protective preparation.
The technical scheme of the invention is as follows:
application of HONGLONGZHENTONG tablet in preparing nerve cell protective preparation is provided.
Preferably, the action mechanism of the Honglong analgesic tablet on the nerve cell protective preparation is a mechanism for eliminating free radicals and reducing NO or NF-kB inflammatory reaction.
Preferably, the Honglong analgesic tablet comprises an extract prepared by a conventional method according to the formulation of the Honglong analgesic tablet.
Preferably, the extract comprises one or more of ethyl acetate extract, ethanol extract and water extract.
Wherein each extract is prepared as follows
Ethyl acetate extract: taking the medicinal materials according to the Honglong analgesic formula and the proportion thereof, adding ethyl acetate with the weight volume ratio of 6-10 times into the other medicinal materials except the bear gall powder and the benzoin, extracting for 2 times, each time for 2 hours, merging the ethyl acetate extracting solutions, concentrating under reduced pressure, continuously drying, adding the bear gall powder and the benzoin, and uniformly mixing to obtain an ethyl acetate extract;
ethanol extraction: taking the medicinal materials according to the Honglong analgesic formula and the proportion thereof, adding 70% ethanol with the weight-volume concentration of 6-10 times of the weight-volume ratio into the other medicinal materials except the bear gall powder and the benzoin for extraction for 2 times, 2 hours for the first time and 1 hour for the second time, combining the two ethanol extract solutions, filtering, concentrating under reduced pressure and continuously drying to obtain an ethanol extract;
water extract: taking the medicinal materials according to the Honglong analgesic formula and the proportion thereof, adding water with the weight volume ratio of 6-10 times into the other medicinal materials except the bear gall powder and the benzoin for extraction for 2 times, 2 hours for the first time and 1.5 hours for the second time, combining the two water extract solutions, filtering, concentrating under reduced pressure and continuously drying to obtain the water extract.
The relationship between the parts by weight and the parts by volume of the invention is g/ml or kg/L.
Compared with the prior art, the invention has the following beneficial effects:
1. the invention overcomes the prejudice of the prior art and provides the Honglong analgesic tablet and the extract thereof with neuroprotective effect for the first time.
2. The neuroprotective effect of the Honglong analgesic tablet is mainly to improve the survival rate of nerve cells by eliminating free radicals, reducing the damage of nerve cells caused by a large amount of NO and the like, and can obviously inhibit the expression of NF-kB in ischemia reperfusion damaged nerve cells, thereby inhibiting the damage effect of inflammatory reaction on the nerve cells.
Detailed Description
The following experimental examples and examples are intended to further illustrate but not limit the invention.
Experimental example 1: protection effect of Honglong analgesic tablets on chemical injury of PC12 cell line caused by glutamic acid
First, experimental material
1. Samples and preparation thereof
Cell line: PC12 cell line (source: Rattus norvegicus adrenal pheochromocytoma, Katy Biotech development Co., Ltd., Nanjing);
reagent: H-DMEM cell culture medium (Hyclone, Saimer Feishale Biochemical Beijing, Inc.); fetal bovine serum (eind biold); pancreatin cell digestive juice (Biyuntian), penicillin streptomycin mixed solution double antibody, cisplatin for injection (Qilu pharmaceutical Co., Ltd.), citrate buffer solution (Beijing Zhonghua fir Jinqiao biotech Co., Ltd.), paraformaldehyde (solarbio), L-glutamic acid (Klonetech, Japan), compound Danshen drop pill (Tianjin Tianshi pharmaceutical Co., Ltd., 20131202)
The red dragon pain-relieving tablet is characterized in that each sample is called as the reference for short:
honglong analgesic tablet (Qinghai gold myrobalan Tibetan medicine, batch number 20141022)
Honglong analgesic tablet ethyl acetate extract (ester extract, self-made in example 1)
Ethanol extract of Honglong analgesic tablet (alcohol extract, self-made in example 1)
Honglong analgesic tablet aqueous extract (aqueous extract, self-made in example 1)
Honglong analgesic tablet micro powder 300 mesh (micro powder, self made in example 1)
2. Laboratory apparatus
A vertical pressure steam sterilization pot (LDZX-50FBS, Shanghai Shenan); double single-side clean bench (SW-CJ-1C, Suzhou clean); carbon dioxide incubator (BB16 μ V/BB5060 μ V, HERAE US); bench centrifuge (H3, Sigma); microplate reader (Multiskan MK3, Thermo Scientific); an electric heating constant temperature blast drying oven (101, shanghai peng shun scientific instruments ltd); inverted microscope (XDS-1B, Chongqing optical instruments factory); a water bath constant temperature oscillator (SHZ-82, medical instrument factory of gold jar city); pipettors (Gilson, Eppendorf); culture flasks (Corning); 96-well plates (Costar, USA).
Second, Experimental methods
A PC12 cytochemical injury model is prepared from glutamic acid, an absorption value is measured at 570nm by adopting a thiazole blue (MTT) method, and the repairing effect of the candidate drug on PC12 cytochemical injury is observed. SOD, NO, LDH and MDA kits are used for detecting the content of each index, and the action mechanism of each medicine is clarified.
Molding: 30mmol/l glutamic acid (this is the final concentration of the sample, dissolved in incomplete medium) acted on PC12 cells for 24 h.
Grouping: blank group, chemical injury model group, chemical injury + drug group, chemical injury + positive control drug group. Because the number of the 96-well plates is limited, two plates are adopted for simultaneous culture and detection when the sample amount is large, and each plate is respectively provided with a model group blank group and a positive control group so as to ensure the reliability and consistency of results.
Third, experimental contents and procedures
1. Cell culture
The frozen PC12 cells were recovered from the ultra-low temperature refrigerator in a culture flask and cultured in H-DMEM medium containing 10% fetal bovine serum. When the PC12 cells grew to 80% confluency, they were digested with 0.25% pancreatin cell digest (containing 0.02% EDTA), seeded into 96-well plates at 1 × 104 cells per well, and wells were zeroed without addition of cells.
2. Cell damage
After the cells in the 96-well plate grow to a monolayer, the culture medium is discarded, sterile PBS is washed for 2 times, and glutamic acid (dissolved in incomplete culture medium) with the final concentration of 30mmol/l is added into each well except for the zero adjustment group and the blank control group to be cultured in an incubator for 24 hours, so that the PC12 cell damage model is generated.
3. Medicated repair
Discarding the culture medium, washing with sterile PBS solution for 2 times, adding 100 μ l DMEM culture medium containing the screened drugs with final concentrations of 100 μ g/ml, 10 μ g/ml and 1 μ g/ml into each well of the administration group, and adding 6 wells for each drug. Taking drug-free DMEM medium as a blank control group, and adding 100 mul of serum-free DMEM medium of compound radix Salviae Miltiorrhizae dripping pills with different concentrations into the positive control group. The cells were then placed in a 5% CO2 incubator at 37 ℃ for further 24 h.
4. Index measurement
4.1 determination of cell viability by MTT method
After the medium is discarded, 100 mul of serum-free DMEM medium is added into each well, and 20 mul of MTT solution with the concentration of 5mg/ml is added into each well to react in an incubator for 4 hours in a dark place. Discarding the culture medium, adding 100 μ l DMSO, measuring OD value at 570nm with enzyme-labeling instrument, and calculating cell survival rate:
calculating the formula: cell survival (%) (drug use or model group a 570/control group a570) × 100%.
4.2 determination of the content of Nitric Oxide (NO), Lactate Dehydrogenase (LDH), superoxide dismutase (SOD), and Malondialdehyde (MDA)
Cell supernatants were collected 24 hours after dosing using sterile tubes, centrifuged for 20 minutes (2000r/min), collected carefully and assayed for LDH, NO content according to kit instructions.
And (3) discarding the supernatant 24 hours after administration, adding 2% Trion-100X, standing at 4 ℃ for 12 hours, uniformly mixing the cell suspension, centrifuging for 20 minutes (2000r/min), carefully collecting the supernatant, and determining the contents of MDA and SOD according to the operation of a kit specification.
Fourth, experimental results
All data are expressed by X +/-SD, and the significance of difference between two comparison groups of single-factor variance analysis and LSD multi-group mean is obvious when P is less than 0.05.
1. Influence of Honglong analgesic tablet on survival rate of injured PC12 cells
Table 1 results of the effect of honglong analgesic tablets on the survival rate of injured PC12 cells (n ═ 8)
Note: denotes P <0.05
The results in table 1 show that the cell survival rates of the candidate drugs with the final concentration of 1 mug/ml are all significantly different from those of the corresponding model groups in alcohol extraction, micro powder extraction, water extraction and ester extraction. In the candidate drugs with the final concentration of 10 mug/ml, the cell survival rate of the ester extraction micro powder is significantly different from that of a model group; the survival rate of the cells extracted by alcohol and water is not obviously different from that of the model group. The fat-soluble components and the Honglong analgesic tablets have stronger protective effect on in-vitro PC12 nerve cells.
2. Influence of Honglong analgesic tablet on LDH, NO, MDA and SOD content
2.1 Effect of Honglong analgesic tablets on the NO content of PC12 cells cultured in vitro
Table 2 determination of NO content in PC12 cells by each extract and serum containing drug of honglong analgesic tablets (n ═ 3)
Note: p <0.05
The results in Table 2 show that the alcohol extraction and ester extraction with final concentration of 1. mu.g/ml and 10. mu.g/ml and the water extraction with final concentration of 10. mu.g/ml are significantly different from the model group; in the serum, the blood drug has significant difference compared with the blank serum group. The results show that each extract and the serum containing the drug have great influence on the NO content of PC12 cells.
2.2 Effect of Red Dragon analgesic tablets on LDH content of PC12 cells cultured in vitro
Table 3 determination of LDH content in each extract and medicated serum of honglong analgesic tablets (n ═ 3)
Note: p <0.05
The results in Table 3 show that 1 microgram/ml, 10 microgram/ml of alcohol extraction, 10 microgram/ml of water extraction and drug-containing serum of the micropowder can obviously reduce the leakage amount of LDH in the damaged PC12 cell culture solution.
2.3 Effect of Honglong analgesic tablets on the SOD content of PC12 cells cultured in vitro
TABLE 4 determination of SOD content in each extract and serum containing drugs of HONGLONGZHENTONG tablet (n ═ 3)
Note: p <0.05
The results in Table 4 show that the ester extract of 1. mu.g/ml, the water extract of 1. mu.g/ml, the ester extract of 10. mu.g/ml and the water extract of 10. mu.g/ml are all significantly different from the model group. The ester extract and the water extract of the Honglong analgesic tablet can obviously improve the SOD concentration of damaged nerve cells and provide about oxidation resistance.
2.4 Effect of Honglong analgesic tablets on the MDA content of PC12 cells cultured in vitro
TABLE 5 content determination of each extract and drug-containing serum MDA of Honglong analgesic tablet (n ═ 3)
Note: p <0.05
The results in table 5 show that there was no significant difference between each group and the model group.
3. Research conclusion of external pharmacological test of Honglong analgesic tablet
TABLE 6 summary of the results of various preparations of HONGLONG analgesic tablet
+ indicates that the preparation or extract had a significant statistical significance (P <0.05) compared to the model group.
3.1 Effect on cell survival
The results of the cell survival rate of the PC12 determined by the MTT method show that the cell survival rate of the candidate drug with the final concentration of 1 mug/ml is significantly different from that of the corresponding model group by alcohol extraction, micropowder extraction, water extraction and ester extraction. In the candidate drug with the final concentration of 10 mug/ml, the survival rate of cells of the micro powder is significantly different from that of the corresponding model group by alcohol extraction. The positive control compound salvia miltiorrhiza dropping pill is administrated at the final concentration of 27mg/ml, and the cell survival rate is highest in each group. The other groups did not show significant difference or were significantly lower than the model control group.
3.2 Effect on SOD content
Compared with the model group, the ester extraction rate is 1 mu g/ml, the water extraction rate is 1 mu g/ml, the ester extraction rate is 10 mu g/ml and the water extraction rate is 10 mu g/ml, the significant differences exist.
3.3 Effect on MDA content
No significant difference was seen between each sample and the model group.
3.4 Effect on NO content
The final concentration of 1 mu g/ml and 10 mu g/ml are significantly different from the model group in alcohol extraction, ester extraction and 10 mu g/ml water extraction; compared with the blank serum group, the serum containing the medicine has obvious difference.
3.5 Effect on LDH content
1 microgram/ml and 10 microgram/ml of micro powder, 10 microgram/ml of alcohol extraction and 10 microgram/ml of water extraction, and the serum containing the medicine has significant differences compared with a model group.
3.6 comprehensive conclusion of Honglong analgesic tablet
The results of the MTT method cell activity screening prove that: compared with a model group, the red dragon pain relieving tablet has obvious repairing effect on PC12 cell damage caused by glutamic acid under the condition of proper concentration of alcohol extract, superfine powder and water extract. Compared with the model group, the ethyl acetate extract and the water extract of the Honglong analgesic tablet can obviously enhance the SOD activity of cells. The medicine has certain effect of eliminating free radical produced by PC12 cell damage caused by glutamic acid.
The micro powder is 1 microgram/ml and 10 microgram/ml, the water extraction is 10 microgram/ml, the alcohol extraction is 10 microgram/ml, the sample with the concentration of 10 microgram/ml, and the serum containing the medicine can reduce the leakage amount of LDH in the culture solution, which indicates that the screened medicines can reduce the damage degree of PC12 nerve cells, and have certain repairing and protecting effects on the nerve cell damage caused by glutamic acid.
The drug-containing serum of the ethyl acetate extract of the Honglong analgesic tablet can obviously reduce the NO content in a cell culture solution and reduce the damage of nerve cells caused by a large amount of NO.
Experimental example 2 protective action of Honglong analgesic tablet on nerve cells after ischemia reperfusion
1 materials and methods
1.1 materials
(1) Animal, wherein two weeks of pregnancy are pregnant two-week Kunming second-level pregnant mice provided by Shandong university animal center;
(2) the main reagent and instrument are fetal calf serum provided by Hangzhou Sijiqing company, and DMEM medium provided by GIBCO company; pancreatin is supplied by huamei corporation; rabbit anti-mouse NF-. kappa.Bp 65 polyclonal antibody (recognizing 1-286 amino acid sequences) was provided by Santa corporation, USA; fluorescein Isothiocyanate (FITC) labeled goat anti-rabbit IgG is supplied by meihua corporation; the beta-tubulin (beta-tubulin) monoclonal antibody is supplied by Progma corporation; honglong analgesic tablet is provided by gold myrobalan Tibetan medicine, and the ethanol extract and the ethyl acetate extract are prepared by the example 1; carbon dioxide incubators are available from SANYO corporation; the flow cytometer is CoulterEliteEPS type, usa.
1.2 methods
(1) Sterilizing a plurality of 25mL culture bottles together, and then coating by polylysine; preparing artificial cerebrospinal fluid, wherein the composition of the artificial cerebrospinal fluid comprises 123mmol/L NaCl, 3.75mmol/L KCl, KH2PO41.25mmol/L NaHCO326mmol/L MgCl21mmol/L CaCl22mmol/L glucose 10mmol/L and the pH value is 7.4.
(2) Cell culture, namely taking two-week pregnant Kunming second-level pregnant mice, dislocating and killing the pregnant mice, disinfecting abdomens with iodine and ethanol, dissecting skin, muscles and peritoneum of the abdomens layer by layer, taking out the fetal mice, carefully peeling amnion of fetal membranes, exposing the fetal mice, peeling meninges under a stereomicroscope, separating cortex of the lateral part of cerebral alveolus of the fetal mice, shearing brain tissues, digesting the fetal mice with trypsin containing 125mg/L (37 ℃/15min), centrifuging the fetal mice for 1000r/min and 10min, discarding supernatant, stopping digestion with DMEM of 200mL/L fetal bovine serum, diluting the fetal mice with complete culture medium (10mL/L fetal bovine serum, cyan and streptomycin 100U/mL) to the density of 7 x 10^5/mL, inoculating the fetal bovine serum, sending the fetal bovine serum into a culture flask treated by polylysine, sending the fetal mice into a 50mL/LCO2 culture box, culturing the fetal mice at 37 ℃ for 48 hours, adding cytarabine (5 mu g/mL) to inhibit the, and (3) replacing the liquid every 2d half, culturing for 10d to obtain typical nerve cells, performing immunofluorescence staining by using the beta-tubulin monoclonal antibody to show that more than 80% of the cells are positive, and culturing the cells to be pure nerve cells, and performing subsequent experimental study.
(3) Establishing an ischemia-like model according to an OGD/R (sugar and other nutrient loss) method, changing a cell culture medium into artificial cerebrospinal fluid without sugar, keeping the temperature at (30 +/-2) DEG C, and changing mixed gas into nitrogen containing 80mL/LCO 2. And (5) carrying out ischemia-like treatment for 10min, replacing the artificial cerebrospinal fluid with the culture medium, putting the artificial cerebrospinal fluid back to an incubator, and reoxygenating.
(4) Counting and detecting by a flow cytometry, namely randomly dividing primary nerve cells (1 x 10^6 bottles) inoculated in a culture bottle into 4 groups, wherein one group is an ischemia-free group, the other group is subjected to similar ischemia treatment and then reoxygenated for 1/2 hours to form an ischemia-reperfusion group, the third group and the fourth group are a treatment group I and a treatment group II, and after the similar ischemia treatment, ethanol extract of Honglong analgesic tablets (treatment group I) and ethyl acetate extract (treatment group II) are respectively added for pretreatment for 10min, wherein the two extracts are respectively diluted into a liquid containing 1mg tablets/ml by adding corresponding solvents into the extract of example 1. Each group of specimens was 4 parts. Group 4 was washed with 0.01moL/LPBS for 5min 3 times, cells were digested with 0.25% trypsin to give a single cell suspension, centrifuged and washed, then 200. mu.L of 1: 200 NF-. kappa.Bp 65 polyclonal antibody was added, the mixture was incubated at 37 ℃ for 45min, washed with 0.01moL/LPBS for 3 times, centrifuged and the supernatant was discarded, 200. mu.L of 1: 50 FITC-labeled anti-rabbit IgG was added, incubated at 4 ℃ for 45min, and washed with 0.01 moL/LPBS. Two negative control groups are additionally arranged, and one negative control group is not added with the I antibody and the II antibody and is used for correcting the fluorescence intensity baseline; another group of samples was treated with II antibody alone as a nonspecific binding control, and all samples were individually subjected to on-machine detection with 400. mu.L of 0.01mol/LPBS solution, and more than 5000 cells were counted per sample, and the results were averaged.
1.3 statistical methods
Results are expressed as x + -s, and comparisons of data between groups were performed by analysis of variance and t-test.
2 results
Flow cytometry results NF-kb/P65 were expressed as (1.38 ± 0.56)%, on a basal basis in non-ischemic neurons, with a significant increase in expression 1/2h after ischemia-reperfusion (P < 0.01). After 2 kinds of extracts of the Honglong analgesic tablets are used for pretreatment, the expression rate is remarkably reduced (P is less than 0.05), and the four groups have remarkable difference (P is less than 0.05). Among them, the ischemia-reperfusion group had a very significant difference (P <0.01) compared to treatment group ii. The ethyl acetate extract has stronger protective effect on the ischemia-reperfusion injury model.
TABLE 1 comparison of NF- κ B expression rates between groups
Note: compared with the non-ischemic group, # # P is less than 0.01; p <0.05, P <0.01 in comparison to ischemia-reperfusion group
3 small knot
NF-kB exists in brain vascular endothelial cells, nerve cells and glial cells, and the expression of the NF-kB is obviously increased after cerebral ischemia reperfusion and is closely related to an inflammation mechanism of cerebral ischemia injury. The experiment examines the intervention and treatment of the red dragon analgesic tablets on the cerebral ischemia-reperfusion injury of the mice by taking NF-kB as an index, and finds that the red dragon analgesic tablets have a remarkable reduction effect on the expression of NF-kB during the cerebral ischemia-reperfusion injury, thereby reducing the damage effect of an inflammation mechanism on the ischemia-reperfusion on nerve cells.
The following examples serve to further illustrate the invention.
Example 1 preparation of extracts from various groups of Honglong analgesic tablets
1) Preparing an ethyl acetate extract of Honglong analgesic tablets:
292g of the Honglong analgesic prescription medicinal materials and the medicinal materials taken according to the proportion are crushed. Extracting the rest materials except fel Ursi powder and Benzoinum for 2 times, adding 2250ml ethyl acetate respectively, extracting for 2h, mixing the ethyl acetate extractive solutions, concentrating under reduced pressure, drying, adding fel Ursi powder and Benzoinum, and mixing to obtain 2.11g ethyl acetate extract of HONGLONGZHENTONG tablet.
2) Preparing an ethanol extract of Honglong analgesic tablets:
292g of the Honglong analgesic prescription medicinal materials and the medicinal materials taken according to the proportion are crushed. Extracting the rest materials except fel Ursi powder and Benzoinum with 2250ml of 70% ethanol by volume for 2 times, 2 hr for the first time, 1 hr for the second time, mixing the two ethanol extractive solutions, filtering, concentrating under reduced pressure, and drying to obtain 11.78g ethanol extract of HONGLONGZHENTONG tablet.
3) Preparing an aqueous extract of Honglong analgesic tablets:
292g of the Honglong analgesic prescription medicinal materials and the medicinal materials taken according to the proportion are crushed. Adding 2820ml of water into other medicinal materials except the bear gall powder and the benzoin, extracting for 2 times, the first time for 2 hours and the second time for 1.5 hours, combining the two water extracts, filtering, concentrating under reduced pressure and continuously drying to obtain 17.84g of water extract of the Honglong analgesic tablets.
4) Honglong analgesic tablet micropowder: pulverizing HONGLONGZHENTONG tablet into fine powder.
5) Preparation of serum containing medicine:
taking ethanol extract of Honglong analgesic tablet, preparing into maximum concentration water suspension, orally feeding 5 mice with dosage of 0.0236g/g body weight, taking eyeball after 30min, taking blood without anticoagulation, centrifuging at 3000rpm for 15min, and separating serum for later use to obtain sample (blood).
Example 2, application of Honglong analgesic tablet in preparing a nerve cell protective preparation.
Example 3, application of Honglong analgesic tablet in preparing nerve cell protective agent, the action mechanism is to clear free radical, reduce NO or NF-kB inflammatory reaction mechanism.
Example 4 application of an ethyl acetate extract of Honglong analgesic tablet in preparing a nerve cell protective preparation, wherein the preparation method of the ethyl acetate extract is the same as that in example 1.
Example 5 application of ethanol extract of Honglong analgesic tablet in preparing nerve cell protective preparation, the preparation method of ethanol extract is the same as example 1.
Example 6 application of water extract of Honglong analgesic tablet in preparing nerve cell protective agent, the preparation method of the water extract is the same as example 1.
Example 7 application of a Honglong analgesic tablet extract composition in preparing a nerve cell protective preparation, the extract composition comprises an ethyl acetate extract and an ethanol extract, and the preparation method of the extract is the same as that of example 1.
Example 8, use of a Honglong analgesic tablet extract composition in the preparation of a neurocyte protective preparation, the extract composition comprising an ethyl acetate extract and a water extract, the extract preparation method being the same as in example 1.
Example 9 application of a Honglong analgesic tablet extract composition in preparing a nerve cell protective preparation, the extract composition comprises a water extract and an ethanol extract, and the preparation method of the extract is the same as that of example 1.
Example 10 application of a Honglong analgesic tablet extract composition in preparing a nerve cell protective preparation, wherein the extract composition comprises an ethyl acetate extract, an ethanol extract and an aqueous extract, and the preparation method of the extract is the same as that of example 1.
The drugs prepared in the above examples all achieved the effects described in experimental example 1 and experimental example 2.
Claims (6)
1. The application of the Honglong analgesic tablet in preparing the nerve cell protective preparation is characterized in that the nerve cell protective preparation has the action mechanism of eliminating free radicals and reducing NO or NF-kB inflammatory reaction mechanism;
the Honglong analgesic tablet is prepared from the following components in percentage by weight: 112.0g of dragon bone, 67.0g of India swertia, 67.0g of safflower, 14.0g of Chrysosplenium, 67.0g of Sichuan yellow chrysanthemum, 14.0g of aconitum pendulum, 67.0g of aconitum tanguticum, 6.6g of bear gall powder, 13.5g of Quanhua, 13.5g of herpetospermum pedunculosum seeds, 13.5g of Maurena, 13.5g of lithospermum, 67.0g of lagotis brachypomus, 13.0g of benzoin and 35.0g of mother-of-pearl.
2. The application of the Honglong analgesic tablet in preparing the nerve cell protection preparation according to claim 1, wherein the Honglong analgesic tablet comprises an extract prepared by a conventional method according to the formulation of the Honglong analgesic tablet.
3. The use of the Honglong analgesic tablet of claim 2 in the preparation of a neuro-cytoprotective preparation, wherein the extract comprises one or more of an ethyl acetate extract, an ethanol extract, and an aqueous extract.
4. The application of the Honglong analgesic tablet in preparing the nerve cell protective preparation according to claim 3 is characterized in that the preparation method of the ethyl acetate extract is as follows:
taking the medicinal materials according to the Honglong analgesic formula and the proportion thereof, adding ethyl acetate with the weight volume ratio g/ml of 6-10 times into the other medicinal materials except the bear gall powder and the benzoin, extracting for 2 times, each time for 2 hours, combining the ethyl acetate extract, concentrating under reduced pressure, continuously drying, adding the bear gall powder and the benzoin, and uniformly mixing to obtain the ethyl acetate extract.
5. The application of the Honglong analgesic tablet in preparing the nerve cell protective preparation according to claim 3 is characterized in that the preparation method of the ethanol extract comprises the following steps:
taking the medicinal materials according to the Honglong analgesic formula and the proportion thereof, adding 70% ethanol with the volume concentration 6-10 times of the weight-volume ratio g/ml into the other medicinal materials except the bear gall powder and the benzoin, extracting for 2 times, extracting for 2 hours for the first time and 1 hour for the second time, combining the two ethanol extracting solutions, filtering, concentrating under reduced pressure and continuously drying to obtain the ethanol extract.
6. The application of the Honglong analgesic tablet in preparing the nerve cell protection preparation according to claim 3 is characterized in that the preparation method of the aqueous extract comprises the following steps:
taking the medicinal materials according to the Honglong analgesic formula and the proportion thereof, adding 6-10 times of water by weight volume ratio g/ml into the other medicinal materials except the bear gall powder and the benzoin, extracting for 2 times, 2 hours for the first time and 1.5 hours for the second time, combining the two water extract solutions, filtering, concentrating under reduced pressure and continuously drying to obtain the water extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610834515.0A CN107837311B (en) | 2016-09-20 | 2016-09-20 | Application of Honglong analgesic tablet in preparation of nerve cell protective preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610834515.0A CN107837311B (en) | 2016-09-20 | 2016-09-20 | Application of Honglong analgesic tablet in preparation of nerve cell protective preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107837311A CN107837311A (en) | 2018-03-27 |
| CN107837311B true CN107837311B (en) | 2021-03-02 |
Family
ID=61657436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610834515.0A Active CN107837311B (en) | 2016-09-20 | 2016-09-20 | Application of Honglong analgesic tablet in preparation of nerve cell protective preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107837311B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631467B (en) * | 2012-05-14 | 2013-07-24 | 山东阿如拉药物研究开发有限公司 | Honglong antalgic medicinal composition, and preparation method and application thereof |
-
2016
- 2016-09-20 CN CN201610834515.0A patent/CN107837311B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107837311A (en) | 2018-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109453212B (en) | A fructus Terminaliae Billericae extract with anticancer effect and its effective components preparation method | |
| CN103446382A (en) | New application of compound traditional Chinese medicine composition | |
| CN112891559B (en) | Polypeptide co-modified naringin nano liposome for promoting proliferation and osteogenic differentiation of dental pulp stem cells and preparation method and application thereof | |
| CN111419869A (en) | Application of lycium barbarum polysaccharide in preparation of medicine for preventing and treating eye diseases | |
| CN111920869B (en) | Traditional Chinese medicine formula for treating tumor-bearing mice by cooperating with chemotherapeutic drugs, preparation method and application | |
| CN107158008B (en) | A kind of pharmaceutical composition for treating myocardial infarction | |
| CN107837311B (en) | Application of Honglong analgesic tablet in preparation of nerve cell protective preparation | |
| CN112402480A (en) | Preparation method and application of eucommia male flower extract with anti-fatigue effect | |
| Park et al. | The neuroprotective and neurotrophic effects of Tremella fuciformis in PC12h cells | |
| CN107890475B (en) | Preparation method of epimedium extract and prepared extract | |
| CN104586866B (en) | A pharmaceutical composition for treating cerebrovascular diseases | |
| CN106389477B (en) | A kind of preparation method and application of the full cellular plant oil extract of Gordonia terrae | |
| CN106389764B (en) | A kind of Chinese materia medica preparation and its preparation and application | |
| CN111978394B (en) | Preparation method of polyclonal preparation for COVID-19 patient specific immunotherapy | |
| CN114671924A (en) | Periplaneta americana polypeptide extract and application thereof in oral cleaning product | |
| CN109602859B (en) | Application of Miao medicine Liaoshi Huafeng Dan in preparing medicine for preventing and treating melanoma | |
| CN110215523B (en) | Application of methyl hispolon in preparation of anti-cervical cancer drugs | |
| CN102389412B (en) | Eye drops for treating cataract | |
| CN111150752A (en) | Application of abrus herb extract in preparing anticancer medicine | |
| CN113616670A (en) | Application of red ginseng pectin-like polysaccharide in preparation of lipid-lowering drugs or health-care products | |
| CN106177035B (en) | Preparation method and application of effective rosa chinensis flower extract with blood sugar reducing and anticancer functions | |
| CN113332296B (en) | Composition for resisting non-small cell lung cancer and application | |
| CN104762253B (en) | The new application of Chinese medicine compound pharmaceutical composition | |
| CN103385899A (en) | Novel application of Chinese medicinal compound pharmaceutical composition | |
| RU2762431C1 (en) | Method for isolation of biologically active substances of antimicrobial action from cell cultures of spiny eleuterococcus eleutherococcus senticosus rupr. maxim. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 250101 Shandong Province Jinan Hi-tech Zone Comprehensive Bonded Zone No. 1 North Section of Gangxing No. 3 Road Jinan Yaogu R&D Platform Area No. 3 Floor 8001 Applicant after: Jinhe Tibetan Medicine (Shandong) Health Industry Co.,Ltd. Address before: 250101 room 501-506, Shun Feng Road, Ji'nan hi tech Zone, Shandong, 501-506 Applicant before: SHANDONG JINHE DRUG RESEARCH DEVELOPMENT Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |